Disease · MONDO_0100135
Trials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 31
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03936777 | A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome | Phase 3 | 412 | 2025-11-17 | Dravet Syndrome, Lennox Gastaut Syndrome, Epileptic Encephalopathy | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02823145 | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome | Phase 3 | 375 | 2023-09-25 | Dravet Syndrome | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02682927 | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome | Phase 3 | 262 | 2022-10-19 | Dravet Syndrome, Seizure Disorder | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03635073 | A Study of Soticlestat in Adults and Children With Rare Epilepsies | Phase 2 | 156 | 2026-03-19 | Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | Phase 3 | 144 | 2025-01-01 | Dravet Syndrome (DS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT03650452 | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies | Phase 2 | 141 | 2021-02-18 | Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02926898 | A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome | Phase 3 | 87 | 2022-10-19 | Dravet Syndrome | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02318602 | Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder | Phase 3 | 52 | 2018-07-26 | Seizures | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT04572243 | A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome | Phase 3 | 22 | 2025-10-08 | Epilepsies, Myoclonic | LORCASERIN | Its record names the disease | ClinicalTrials.gov |
| NCT02758626 | Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome | Phase 2 | 15 | 2023-02-16 | Epilepsy | ATALUREN | Its record names the disease | ClinicalTrials.gov |
| NCT02187809 | Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome | Phase 3 | 3 | 2017-02-15 | Dravet Syndrome | CLOBAZAM | Its record names the disease | ClinicalTrials.gov |
| NCT04485104 | Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures | Phase 3 | 3 | 2025-10-31 | Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
| NCT01607073 | Verapamil as Therapy for Children and Young Adults With Dravet Syndrome | Phase 2 | 2 | 2021-03-23 | Dravet Syndrome | VERAPAMIL | Its record names the disease | ClinicalTrials.gov |
| NCT06422377 | A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine | Phase 3 | 1 | 2025-03-06 | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | Phase 3 | 352 | Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS) | SOTICLESTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT06872125 | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | Phase 3 | 170 | Dravet Syndrome | ZOREVUNERSEN | Its record names the disease | ClinicalTrials.gov | |
| NCT05485831 | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY | 111 | Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov | ||
| NCT06118255 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome | Phase 3 | 25 | Dravet Syndrome | FENFLURAMINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06738732 | CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome | Phase 1/2 | 25 | Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov | |
| NCT06924827 | A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to Epidiolex | Phase 4 | 25 | Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS) | CANNABIDIOL | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100135/trials